Best of SIR 2013



If you are not automatically redirected, please click here.

Live
On Demand
Best of SIR 2013: PAD

Learning Objectives
After participating in this activity, learners should be able to:

Describe recent developments in the area of critical limb ischemia and below-knee interventions
Describe methods for predicting and securing successful clinical outcomes from revascularization in patients with lower extremity arterial occlusive disease
Describe the role of new direct drug delivery platforms in CLI
Identify advanced technical strategies for successful trans-catheter revascularization

Speakers

The Time is Now
Robert A. Lookstein, M.D., FSIR, Mount Sinai Hospital, New York, N.Y.

Predicting Outcomes in CLI Revascularization
Irene Bargellini, M.D., University of Pisa, Italy

Pedal Loop, SAFARI, and Other Advanced Techniques
Marco G. Manzi, M.D., Policlinico Abano Terme, Italy

Drugs: Mechanism of Action, FDA Approved Platforms, Future Horizons
Mahmood K. Razavi, M.D., FSIR, St. Joseph Vascular Institute, Irvine, Calif.

Forecast for the future: Corporate market analysis
Tammy Leitsinger, Cordis Corporation, Lebanon, Ohio


Best of SIR 2013: PAD

Learning Objectives
After participating in this activity, learners should be able to:

Describe recent developments in the area of critical limb ischemia and below-knee interventions
Describe methods for predicting and securing successful clinical outcomes from revascularization in patients with lower extremity arterial occlusive disease
Describe the role of new direct drug delivery platforms in CLI
Identify advanced technical strategies for successful trans-catheter revascularization

Speakers

The Time is Now
Robert A. Lookstein, M.D., FSIR, Mount Sinai Hospital, New York, N.Y.

Predicting Outcomes in CLI Revascularization
Irene Bargellini, M.D., University of Pisa, Italy

Pedal Loop, SAFARI, and Other Advanced Techniques
Marco G. Manzi, M.D., Policlinico Abano Terme, Italy

Drugs: Mechanism of Action, FDA Approved Platforms, Future Horizons
Mahmood K. Razavi, M.D., FSIR, St. Joseph Vascular Institute, Irvine, Calif.

Forecast for the future: Corporate market analysis
Tammy Leitsinger, Cordis Corporation, Lebanon, Ohio


test
Renal Denervation: A Primer for Radiologists

Renal denervation is currently in evaluation for various diseases including resistant hypertension, cardiac failure and others. This course will review the pathophysiology, the clinical evidence for renal denervation in resistant hypertension. Most available materials will also be discussed.

Objective
At the end of this session, the learner should be able to: 1.Identify resistant hypertension and describe the role of sympathetic hyperactivity 2.Describe the basics of renal denervation using radiofrequency ablation and other recent technologies 3.Discuss the status of clinical evidence for denervation in resistant hypertension

CME credits for paid registrants = 1.5

Coordinator


Dr. Marc R. Sapoval, MD, PhD, Hopital Europeen Georges Pompidou

Moderator


Dr. Hicham T. Abada, MD, Chandler Hospital

Speaker(s)


Prof. Michel Azizi, MD, PhD, Georges Pompidou European Hospital


Dr. Dagmara Hering,MD, PhD, Baker IDI Heart and Diabetes Institute


Dr. Michael J. Lee, MD, FRCR, FSIR Beaumont Hospital


Dr.Barry T. Katzen, MD, FSIR, Baptist Cardiac & Vascular Institute


Eric Wyffels, Aalst




Panelist(s)


Dr. Mahmood K. Razavi, MD, FSIR, St Joseph Vascular Institute


Dr. Timothy P. Murphy, MD, FSIR, Rhode Island Hospital






Venous Thromboembolic Disease: The Essentials for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Management

The VTE categorical course will review the guidelines, protocols and pearls for imaging, treatment and post procedural care in patients with acute and chronic DVT. The PE portion will review the latest guidelines, protocols and clinical pearls for treating submassive and massive acute PE as well as discussing tips for building a VTE practice

Objective
At the end of this session, the learner should be able to: 1.Summarize the latest guidelines for the medical management of patients with DVT and PE 2.Discuss the rationale for treatment as well as current guidelines for interventional therapies in patients with DVT and PE 3.List the treatment options available for patients being evaluated for acute & chronic DVT as well as submassive & massive PE

CME credits for paid registrants = 1.5

Coordinator


Dr. Mark J. Garcia,MD, FSIR, Christiana Care Health Services

Moderator(s)


Dr. William T. Kuo, MD, FSIR, Stanford University Medical Center


Dr. Mark J. Garcia,MD, FSIR, Christiana Care Health Services

Speaker(s)


Shelly Brancatelli, Cleveland Clinic


Dr. Robert A. Lookstein, MD, FSIR, Mount Sinai Hospital


Dr. Mark J. Garcia,MD, FSIR, Christiana Care Health Services


Dr. Suresh Vedantham, MD, FSIR, Mallinckrodt Institute of Radiology


Donald Schreiber, MD,CM, Stanford University School of Medicine


Dr. Akhilesh K. Sista, MD, Weill Cornell Medical College


Dr. Paul Kim, MD, Spectrum Medical Group


Dr. William T. Kuo, MD, FSIR, Stanford University Medical Center




Panelist(s)


Dr. Robert A. Lookstein, MD, FSIR, Mount Sinai Hospital


Dr. Mark J. Garcia,MD, FSIR, Christiana Care Health Services


Dr. Suresh Vedantham, MD, FSIR, Mallinckrodt Institute of Radiology


Dr. William T. Kuo, MD, FSIR, Stanford University Medical Center


Dr. Paul Kim, MD, Spectrum Medical Group


Dr. Akhilesh K. Sista, MD, Weill Cornell Medical College


Donald Schreiber, MD,CM, Stanford University School of Medicine






Advanced Critical Limb Ischemia (CLI) Intervention

This session will focus on new and critical concepts in the care of complex patients with critical limb ischemia. The attendee will learn about advanced technical concepts, as well as strategies for success in caring for patients with advanced lower-extremity atherosclerotic disease.

Objective
At the end of this session, the learner should be able to: 1.Describe methods for predicting and securing successful clinical outcomes from revascularization in patients with lower extremity arterial occlusive disease 2.Describe the role of new direct drug delivery platforms in CLI 3.Identify advanced technical strategies for successful trans-catheter revascularization

CME credits for paid registrants = 1.5

Coordinator


Dr. Laura Findeiss, MD, FSIR, University of California at Irvine School of Medicine

Moderator


Dr. Bret N. Wiechmann, MD, FSIR, Vascular & Interventional Physicians

Speaker(s)


Dr. Laura Findeiss, MD, FSIR, University of California at Irvine School of Medicine


Dr. Bret N. Wiechmann, MD, FSIR, Vascular & Interventional Physicians


Irene Bargellini, University of Pisa


Dr. John H. Rundback, MD, Advanced Interventional Radiology Services, LLP


Dr. Marco Manzi, Policlinico Abano Terme


Dr. Mahmood K. Razavi, MD, FSIR, St Joseph Vascular Institute


Dr. Robert A. Hieb, MD, FSIR, Medical College of Wisconsin




Panelist(s)


Irene Bargellini, University of Pisa



Dr. John H. Rundback, MD, Advanced Interventional Radiology Services, LLP


Dr. Marco Manzi, Policlinico Abano Terme






Backstage Access: Dialysis Interventions 2013

This course will concentrate on the status of hemodialysis access interventions in the Fistula First era. We will focus on what IR clinicians can offer to contribute to the Fistula First effort, as well as to the growing movement to reduce catheter use to the absolute minimum necessary. We will focus on evidence basis including the present controversy concerning prophylactic PTA, the limited role of stents and stent grafts, and related topics.

Objective
At the end of this session, the learner should be able to: 1.Describe the Fistula First initiative and the related 'catheter last' movement 2.List three ways in which IR clinicians directly contribute to the Fistula First initiative 3.Explain the evidentiary basis for a preference of stent grafts over stents, in the uncommon situations these devices are indicated 4.Describe the difference in outcomes of IR interventions expected for fistulae and grafts

CME credits for paid registrants = 1.5

Coordinator


Dr. Scott O. Trerotola, MD, FSIR, University of Pennsylvania Medical Center

Moderator


Dr. Gordon McLennan,MD, FSIR, Cleveland Clinic

Speaker(s)


Dr. Michael Allon, University of Alabama Birmingham


Dr. Thomas M. Vesely, MD, FSIR, Vascular Access Services, LLC


Dr. Timothy W.I. Clark, MD, FSIR, Penn Presbyterian Medical Center


Dr. Bart L. Dolmatch, MD, FSIR, Palo Alto Medical Foundation


Dr. Karim Valji, MD, FSIR, University of Washington


Best of SIR 2013: Interventional Oncology

Program Description
This live online event is a rebroadcast of the popular session, Management of Patients with Hepatocellular Carcinoma, from the SIR 2013 Annual Scientific Meeting. Faculty will be online during the broadcast to interact with attendees and answer questions.The presentation explains the epidemiology of hepatocellular carcinoma (HCC), and the meaning of systemic targeted agents and molecular biomarkers. Experts in the treatment of HCC review the various stages and available treatments of HCC, as well as the risks of and outcomes following those treatments.

Learning Objectives

After participating in this activity, learners should be able to:

1.Describe the epidemiology of hepatocellular carcinoma (HCC)
2.Explain the meaning of systemic targeted agents and molecular biomarkers
3.Summarize the various stages of HCC and the indications for all available treatments
4.Identify the benefits and potential risk of the various treatments for HCC

CME Credit

The Society of Interventional Radiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Society of Interventional Radiology designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Talk Titles

Distinguished Abstract: Transcatheter intraarterial delivery of superparamagentic iron oxide-labeled natural killer lymphocytes to hepatocellular carcinoma: longitudinal efficacy studies in a rat model, Alexander Sheu
Epidemiology and Staging of HCC, Ghassan Abou-Alfa, MD and David Cosgrove, MD
Targeted Agents: Sorafenib and beyond, David Cosgrove, MD
Importance of Biomarkers and Tailoring Therapy, David Cosgrove, MD
Early HCC, Robert Lewandowski, MD, FSIR
Management of Intermediate-Advanced HCC, Jeff Geschwind, MD, FSIR

Speaker(s)


Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York, N.Y.


David Cosgrove, MD,Johns Hopkins University, Baltimore, Md.


Robert Lewandowski, MD, FSIR, Northwestern Memorial Hospital, Chicago, Ill.


Jeff Geschwind, MD, FSIR, Interventional Radiology Center- The Johns Hopkins Hospital, Baltimore, Md.


Alexander Sheu, Northwestern University - Feinberg School of Medicine, Chicago Ill.





Best of SIR 2013: Venous Interventions

Program Description
This live online event will rebroadcast selected venous disease focused presentations from the SIR 2013 Annual Scientific Meeting. Faculty will be online during the broadcast to interact with attendees and answer questions. The rebroadcast will review the guidelines, protocols and pearls for imaging, treatment and post procedural care in patients with acute and chronic DVT. The PE portion will review the latest guidelines, protocols and clinical pearls for treating submassive and massive acute PE.

Learning Objectives

After participating in this activity, learners should be able to:

1.Summarize the latest guidelines for the medical management of patients with DVT and PE
2.Discuss the rationale for treatment as well as current guidelines for interventional therapies in patients with DVT and PE
3.List the treatment options available for patients being evaluated for acute & chronic DVT as well as submassive & massive PE

CME Credit

The Society of Interventional Radiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Society of Interventional Radiology designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Speaker(s)


Common Femoral Vein waveform analysis – Neil M. Khilnani, MD, Cornell Vascular, New York, NY


Deciding on which lytic tool & what tricks to use – Robert A. Lookstein, MD, FSIR, Mount Sinai Hospital, New York, NY


Changing the landscape of DVT and PTS – Mark J. Garcia, MD, FSIR, University of New Mexico, Albuquerque, NM


Algorithm of CDT for Massive PE – William T. Kuo, MD, Stanford University Medical Center, Palo Alto, CA


Post procedure management for venous disease – Suresh Vedantham, MD, FSIR, Mallinckrodt Institute of Radiology, Saint Louis, MO





Conversion
Conversion 11.14
Extreme IR

Come to Extreme IR for ingenuity, innovation...and stress. See rapid-fire presentations and discussions of innovative IR and endovascular cases, solutions, and diagnostic and therapeutic dilemmas. Witness what presenters have done when faced with the need for something that has not been seen nor done before, for which the right tools may not exist. This is the extreme IR zone.

Objective
At the end of this session, the learner should be able to: 1.Describe novel and complex embolizations in vascular and nonvascular applications 2.Review the use of innovative tools in arterial and venous obstruction and bleeding 3.Analyze the use of implantable devices, such as stents and stent grafts in atypical and/or emergent scenarios

CME credits for paid registrants = 1.5

Coordinator


Prof. Ziv J. Haskal, MD, FSIR, University of Maryland

Moderator


Dr. Michael D. Dake, MD, Falk Cardiovascular Research Center

Speaker(s)


Dr. Bart L. Dolmatch,MD, FSIR, Palo Alto Medical Foundation


Dr. Riad Salem, MD, MBA, FSIR, Northwestern Memorial Hospital


Dr. John F. Angle, MD, University of Virginia Health System


Dr. Matthew S. Johnson, MD, FSIR, Indiana University School of Medicine


Dr. Mahmood K. Razavi, MD, FSIR, St Joseph Vascular Institute



Dr. Stephen T. Kee, MD, FSIR, Ronald Reagan UCLA Medical Center


Prof. Ziv J. Haskal, MD, FSIR, University of Maryland


Dr. Michael D. Dake, MD, Falk Cardiovascular Research Center


Dr. James F. Benenati, MD, FSIR Baptist Cardiac & Vascular Institute


Professor Johannes Lammer, MD, University Clinics Vienna


Professor Kimihiko Kichikawa, MD, Nara Medical University


Dr. L. Nelson Hopkins, MD, Jacobs Institute/UB Neurosurgery, Inc.


Dr. Shaun L. Samuels, MD, FSIR, Baptist Cardiac and Vasc. Institute





Imaging Guidance/Targeting and Emerging Therapies for Cancer

Objective
At the end of this session, the learner should be able to: 1.Describe the role of cone beam CT imaging during intra-arterial therapy for liver cancer 2.Explain the role of molecular imaging to guide local treatment for cancer 3.Summarize the various imaging response criteria and identify the pros and cons of each 4.Discuss the new ablative techniques and intra-arterial therapies

CME credits for paid registrants = 1.5

Coordinator


Dr. Jeff H. Geschwind, MD, FSIR, Interventional Radiology Center- The Johns Hopkins Hospital

Moderator(s)


Professor Riccardo A. Lencioni,MD, FSIR, EBIR, University of Pisa


Dr. Kamran Ahrar, MD, MD Anderson Cancer Center

Speaker(s)


Mikhail Silk, Memorial Sloan-Kettering Cancer Center


Dr. MingDe Lin, Philips Research North America


Dr. Bradford Johns Wood, MD, National Institutes of Health, National Cancer Institute


Dr. Stephen B. Solomon, MD, FSIR, Memorial Sloan Kettering Cancer Center


Dr. Riad Salem, MD, MBA, FSIR, Northwestern Memorial Hospital


Professor Riccardo A. Lencioni,MD, FSIR, EBIR, University of Pisa


Dr. Jeff H. Geschwind, MD, FSIR, Interventional Radiology Center- The Johns Hopkins Hospital




Reproductive Embolotherapy

This categorical course will focus on embolization procedures in the male and female pelvis. This will include an update on prostate embolization and the fundamentals of practice development in this area. It will also include updates on varicocele embolization, embolization for pelvic congestion syndrome and uterine fibroid embolization, with particular attention on current and future embolic agents and management of complications.

Objective
At the end of the session the learner should be able to: 1. Describe the anatomy of the prostate gland and the technique of prostate embolization 2. Identify strategies for developing a prostate embolization practice 3. Explain how to diagnose and treat pelvic congestion syndrome and scrotal varicocele 4. Review current and future embolic agents for uterine artery embolization 5. Summarize the recent advances in UAE for fibroid disease 6. Manage complications of uterine artery embolization for fibroids

CME credits for paid registrants = 1.5

Coordinator


Dr. Gary P. Siskin, MD, FSIR, Albany Medical College

Moderator(s)


Dr. Richard Shlansky-Goldberg, MD, FSIR, University of Penn. Med Ctr.


Dr. Gary P. Siskin, MD, FSIR, Albany Medical College

Speaker(s)


Prof. Francisco Cesar Carnevale, MD., PhD., University of Sao Paulo Medical School


Dr. Gary P. Siskin, MD, FSIR, Albany Medical College


Dr. Lindsay Machan, MD, FSIR, University of British Columbia Hospital


Dr. Anthony C. Venbrux, MD, FSIR, George Washington Univ Med Ctr


Dr. James B. Spies, MD, MPH, FSIR, Georgetown University Medical Center


Professor Jean-Pierre Pelage,MD, PhD, Department of Radiology CHU de Caen


Dr. Richard Shlansky-Goldberg, MD, FSIR, University of Penn. Med Ctr.


Dr. Tiago A. Bilhim, MD, PhD, Saint Louis Hospital




test
Test
Tumor Board on HCC and Colorectal Liver Metastases

This course will concentrate on the status of hemodialysis access interventions in the Fistula First era. We will focus on what IR clinicians can offer to contribute to the Fistula First effort, as well as to the growing movement to reduce catheter use to the absolute minimum necessary. We will focus on evidence basis including the present controversy concerning prophylactic PTA, the limited role of stents and stent grafts, and related topics.

Objective
At the end of this session, the learner should be able to: 1.Describe the Fistula First initiative and the related 'catheter last' movement 2.List three ways in which IR clinicians directly contribute to the Fistula First initiative 3.Explain the evidentiary basis for a preference of stent grafts over stents, in the uncommon situations these devices are indicated 4.Describe the difference in outcomes of IR interventions expected for fistulae and grafts

CME credits for paid registrants = 1.5

Coordinator


Dr. Scott O. Trerotola, MD, FSIR, University of Pennsylvania Medical Center

Moderator


Dr. Gordon McLennan,MD, FSIR, Cleveland Clinic

Speaker(s)


Dr. Michael Allon, University of Alabama Birmingham


Dr. Thomas M. Vesely, MD, FSIR, Vascular Access Services, LLC


Dr. Timothy W.I. Clark, MD, FSIR, Penn Presbyterian Medical Center


Dr. Bart L. Dolmatch, MD, FSIR, Palo Alto Medical Foundation


Dr. Karim Valji, MD, FSIR, University of Washington


April 14th
April 15th
April 16th
April 17th
November 14th
October 24th
On Demand
Cook Medical
Host Space [1082]
Sirtex
Badge Leaderboard
Boston Scientific
Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 24,000 employees and revenue of $7.622 billion in 2011. For more than 30 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The Company’s products help physicians and other medical professionals improve their patients’ quality of life by providing alternatives to surgery. For more information, please visit www.bostonscientific.com.
Boston Scientific, medical device, peripheral interventions, interventional cardiology, interventional radiology, endoscopy, radio frequency ablation, stent, renal denervation, balloon dilatation catheter, catheter, CTO, guidewire, support catheter, controlwire, detachable coil, Renegade, Interlock, Vessix, TruePath, Rubicon, WallFlex, Mustang, Coyote, V-14
Cook Medical
Cook
We believe there are no limits to what you can do—whether you’re fighting cancer, treating aortic disease, or combating PAD. That’s why for 50 years, Cook Medical has offered more than just proven interventional products. With Cook Medical, you can also: